Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh‐mismatched transfusions in children?
Transfusion · 2026
DOI: 10.1111/trf.70094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2026. Verfasst von Kirea Lange und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Perioperative Care, Dell Medical School, University of Texas at Austin, Austin, Texas, USA. Hauptthemen laut MEDLINE: Rho(D) Immune Globulin, Rh-Hr Blood-Group System, Rh Isoimmunization, Transfusion Reaction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
RhD mismatched transfusions in RhD negative women have the potential to impact future pregnancies through alloimmunization and development of hemolytic disease of the fetus and newborn (HDFN). As use of RhD positive emergency‐release blood products in pediatric trauma has increased, it has become clear that a significant alloimmunization risk also exists for RhD negative girls, which has not been addressed by existing literature. This article describes a best‐practice guideline to manage RhD negative pediatric females who receive RhD positive transfusions.
Design
Pathology or transfusion medicine staff are notified of RhD‐mismatched blood transfusions and eligibility for therapy with RhIG is determined. Patients are evaluated by Pediatrics or Pediatric Hematology. These consultants will provide counseling and offer treatment.
Results
Management strategy depends on red blood cell volume (RBCv) transfused. Pediatric females who receive RBCv 20% are not. Unlike in adult females, TBV calculations change with age. All should be screened for the development of anti‐D antibodies between 6 and 12 months after transfusion, regardless of treatment with RhIG. When the patient reaches adulthood, she should be followed by ObGyn and undergo repeat antibody testing before becoming pregnant.
Conclusion
Protocols for the management of mismatched transfusions in RhD negative women have been established, but there are no published guidelines directing management of similar pediatric patients. The described approach provides a safe and effective framework to mitigate RhD alloimmunization risk for these pediatric patients, thereby safeguarding their future reproductive outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Perioperative Care, Dell Medical School, University of Texas at Austin, Austin, Texas, USA.
- Department of Surgery, University of Texas at San Antonio, San Antonio, Texas, USA.
- Residents and Fellows Trauma Advocacy Coalition, San Antonio, Texas, USA.
- Department of Pathology and Laboratory Medicine, UT Health at San Antonio, San Antonio, Texas, USA.
- Trauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Zitieren
APA
Lange, K., Bowers, A., Raghavan, N., Borland, H., Greebon, L., Leeper, C., Gaines, B., & Jenkins, D. (2026). Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh‐mismatched transfusions in children?. Transfusion. https://doi.org/10.1111/trf.70094
Vancouver
Lange K, Bowers A, Raghavan N, Borland H, Greebon L, Leeper C, et al. Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh‐mismatched transfusions in children?. Transfusion. 2026. doi:10.1111/trf.70094
BibTeX
@article{Lange2026,
author = {Lange, Kirea and Bowers, Alexander and Raghavan, Niruktha and Borland, Hannah and Greebon, Leslie and Leeper, Christine and Gaines, Barbara and Jenkins, Donald},
title = {Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh‐mismatched transfusions in children?},
journal = {Transfusion},
year = {2026},
doi = {10.1111/trf.70094}
}
EUVIMED